Adherence to antiepileptic medicines in children: A multiple-methods assessment involving dried blood spot sampling

Epilepsia

Volumn 54, Issue 6, 2013, Pages 1020-1027

  Shah, Noraida Mohamed ^a,b   Hawwa, Ahmed F ^a   Millership, Jeff S ^a   Collier, Paul S ^a   Ho, Paul ^c   Tan, Mui Ling ^c   Peake, Deirdre ^d   Tirupathi, Sandya ^d   Bothwell, Janice ^d   Bailie, Nicola ^e   Shepherd, Charles ^f   Craig, John ^g   McElnay, James C ^a  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^b UNIVERSITI KEBANGSAAN MALAYSIA   (Malaysia)

^c NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^d ROYAL GROUP OF HOSPITALS TRUST   (United Kingdom)

^e NORTHERN HEALTH AND SOCIAL CARE TRUST   (United Kingdom)

^f SOUTHERN HEALTH AND SOCIAL CARE TRUST   (United Kingdom)

^g ROYAL VICTORIA HOSPITAL   (United Kingdom)

Author keywords

Adherence; Depressed mood; Dried blood spots; Epilepsy; MARS

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; ETIRACETAM; LAMOTRIGINE; TOPIRAMATE; VALPROIC ACID;

ADOLESCENT; ANTICONVULSANT THERAPY; ARTICLE; BENIGN CHILDHOOD EPILEPSY; CHILD; DEPRESSION; DRIED BLOOD SPOT TESTING; DRUG BLOOD LEVEL; FEMALE; FOCAL EPILEPSY; GENERAL PRACTITIONER; GENERALIZED EPILEPSY; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; PARENT; PATIENT ASSESSMENT; PATIENT COMPLIANCE; PRESCRIPTION; PRIORITY JOURNAL; SAMPLING; SCHOOL CHILD; SELF REPORT; TREATMENT REFUSAL;

ADOLESCENT; ANTICONVULSANTS; CHILD; CHILD, PRESCHOOL; DEPRESSION; EPILEPSY; EPILEPSY, GENERALIZED; FEMALE; HUMANS; INFANT; LOGISTIC MODELS; MALE; MEDICATION ADHERENCE; PARENTS; PSYCHIATRIC STATUS RATING SCALES; PSYCHOLOGICAL TESTS; SELF REPORT;

EID: 84878560424     PISSN: 00139580     EISSN: 15281167     Source Type: Journal    
DOI: 10.1111/epi.12126     Document Type: Article

References (51)

1. Ahmad AM, Douglas Boudinot F, Barr WH, Reed RC, Garnett WR,. (2005) The use of Monte Carlo simulations to study the effect of poor compliance on the steady state concentrations of valproic acid following administration of enteric-coated and extended release divalproex sodium formulations. Biopharm Drug Dispos 26: 417-425.
2. Andersson K, Melander A, Svensson C, Lind O, Nilsson JLG,. (2005) Repeat prescriptions: refill adherence in relation to patient and prescriber characteristics, reimbursement level and type of medication. Eur J Public Health 15: 621-626.
3. Asadi-Pooya AA,. (2005) Drug compliance of children and adolescents with epilepsy. Seizure 14: 393-395.
4. Austin JK, MacLeod J, Dunn DW, Shen J, Perkins SM,. (2004) Measuring stigma in children with epilepsy and their parents: instrument development and testing. Epilepsy Behav 5: 472-482.
5. Chhun S, Jullien V, Rey E, Dulac O, Chiron C, Pons G,. (2009) Population pharmacokinetics of levetiracetam and dosing recommendation in children with epilepsy. Epilepsia 50: 1150-1157.
6. Conn KM, Halterman JS, Fisher SG, Yoos HL, Chin NP, Szilagyi PG,. (2005) Parental beliefs about medications and medication adherence among urban children with asthma. Ambul Pediatr 5: 306-310.
7. Cramer JA, Westbrook LE, Devinsky O, Perrine K, Glassman MB, Camfield C,. (1999) Development of the quality of life in epilepsy inventory for adolescents: the QOLIE-AD-48. Epilepsia 40: 1114-1121.
8. Daniels T, Goodacre L, Sutton C, Pollard K, Conway S, Peckham D,. (2011) Accurate assessment of adherence: self and clinician report versus electronic monitoring of nebulizers. Chest 140: 425-432.
9. Davis KL, Candrilli SD, Edin HM,. (2008) Prevalence and cost of non-adherence with antiepileptic drugs in an adult managed care population. Epilepsia 49: 446-454.
10. DiMatteo MR, Lepper HS, Croghan TW,. (2000) Depression is a risk factor for noncompliance with medical treatment: meta-analysis of the effects of anxiety and depression on patient adherence. Arch Intern Med 160: 2101-2107.
11. Dunbar-Jacob J, Mortimer-Stephens MK,. (2001) Treatment adherence in chronic disease. J Clin Epidemiol 54: S57-S60.
12. Edelbroek P,. (2002) Bloedspotmethode biedt nieuwe perspectieven voor bloedspiegelbepalingen: therapeutic drug monitoring van anti-epileptica = Therapeutic drug monitoring of antiepileptic agents. Blood spot method presents new perspectives for blood level determinations. Pharm Weekbl 137: 519-524.
13. Faught E, Duh MS, Weiner JR, Guerin A, Cunnington MC,. (2008) Nonadherence to antiepileptic drugs and increased mortality: findings from the RANSOM study. Neurology 71: 1572-1578.
14. Gomes MM, Maia Filho HS,. (1998) Medication-taking behavior and drug self regulation in people with epilepsy. Arq Neuropsiquiatr 56: 714-719.
15. Hazzard A, Hutchinson SJ, Krawiecki N,. (1990) Factors related to adherence to medication regimens in pediatric seizure patients. J Pediatr Psychol 15: 543-555.
16. Hess LM, Raebel MA, Conner DA, Malone DC,. (2006) Measurement of adherence in pharmacy administrative databases: a proposal for standard definitions and preferred measures. Ann Pharmacother 40: 1280-1288.
17. Horne R,. (2005) Section 1: introduction. In, Horne R, Weinman J, Barber N, Elliott R, Morgan M, (Eds) Concordance, adherence and compliance in medicine-taking. Report for the National Co-ordinating Centre for NHS Service Delivery and Organisation R & D. Available at: http://www.sdo.nihr.ac.uk/ files/project/76-final-report.pdf (last accessed 1 September 2011).
18. Horne R, Hankins M,. (2008) The medication adherence report scale (MARS): a new measurement tool for eliciting patients' reports of non-adherence. The School of Pharmacy, University of London, London, UK.
19. Horne R, Weinman J, Hankins M,. (1999) The beliefs about medicines questionnaire: the development and evaluation of a new method for assessing the cognitive representation of medication. Psychol Health 14: 1-24.
20. Hovinga CA, Asato MR, Manjunath R, Wheless JW, Phelps SJ, Sheth RD, Pina-Garza JE, Zingaro WM, Haskins LS,. (2008) Association of non-adherence to antiepileptic drugs and seizures, quality of life, and productivity: survey of patients with epilepsy and physicians. Epilepsy Behav 13: 316-322.
21. Hussein Z, Posner J,. (1997) Population pharmacokinetics of lamotrigine monotherapy in patients with epilepsy: retrospective analysis of routine monitoring data. Br J Clin Pharmacol 43: 457-465.
22. Jones RM, Butler JA, Thomas VA, Peveler RC, Prevett M,. (2006) Adherence to treatment in patients with epilepsy: associations with seizure control and illness beliefs. Seizure 15: 504-508.
23. Kemp S, Feely M, Hay A, Wild H, Cooper C,. (2007) Psychological factors and use of antiepileptic drugs: pilot work using an objective measure of adherence. Psychol Health Med 12: 107-113.
24. Kyngäs H,. (2000) Compliance with health regimens of adolescents with epilepsy. Seizure 9: 598-604.
25. Landis JR, Koch GG,. (1977) The measurement of observer agreement for categorical data. Biometrics 33: 159-179.
26. Lisk DR, Greene SH,. (1985) Drug compliance and seizure control in epileptic children. Postgrad Med J 61: 401-405.
27. Maitre PO, Ausems ME, Vozeh S, Stanski DR,. (1988) Evaluating the accuracy of using population pharmacokinetic data to predict plasma concentrations of alfentanil. Anesthesiology 68: 59-67.
28. Milovanovic JR, Jankovic SM,. (2009) Population pharmacokinetics of lamotrigine in patients with epilepsy. Int J Clin Pharmacol Ther 47: 752-760.
29. Mitchell WG, Scheier LM, Baker SA,. (2000) Adherence to treatment in children with epilepsy: who follows "doctor's orders"? Epilepsia 41: 1616-1625.
30. Modi AC, Morita DA, Glauser TA,. (2008) One-month adherence in children with new-onset epilepsy: white-coat compliance does not occur. Pediatrics 121: e961-e966.
31. Modi AC, Guilfoyle SM, Morita DA, Glauser TA,. (2011a) Development and reliability of a correction factor for parent-reported adherence to pediatric antiepileptic drug therapy. Epilepsia 52: 370-376.
32. Modi AC, Rausch JR, Glauser TA,. (2011b) Patterns of nonadherence to antiepileptic drug therapy in children with newly diagnosed epilepsy. JAMA 305: 1669-1676.
33. Osterberg L, Blaschke T,. (2005) Adherence to medication. N Engl J Med 353: 487-497.
34. Otero S, Hodes M,. (2000) Maternal expressed emotion and treatment compliance of children with epilepsy. Dev Med Child Neurol 42: 604-608.
35. Paschal AM, Hawley SR, Romain TS, Ablah E,. (2008) Measures of adherence to epilepsy treatment: review of present practices and recommendations for future directions. Epilepsia 49: 1115-1122.
36. Radloff L,. (1977) The CES-D scale: a self-report depression scale for research in the general population. Appl Psychol Measurement 3: 385-401.
37. Reed R, Dutta S,. (2004) Predicted serum valproic acid concentrations in patients missing and replacing a dose of extended-release divalproex sodium. Am J Health Syst Pharm 61: 2284-2289.
38. Reith DM, Hooper WD, Parke J, Charles B,. (2001) Population pharmacokinetic modeling of steady state carbamazepine clearance in children, adolescents, and adults. J Pharmacokinet Pharmacodyn 28: 79-92.
39. Serrano BB, Garcia Sanchez MJ, Otero MJ, Buelga DS, Serrano J, Dominguez-Gil A,. (1999) Valproate population pharmacokinetics in children. J Clin Pharm Ther 24: 73-80.
40. Shank RP, Doose DR, Streeter AJ, Bialer M,. (2005) Plasma and whole blood pharmacokinetics of topiramate: the role of carbonic anhydrase. Epilepsy Res 63: 103-112.
41. Shope JT,. (1988) Compliance in children and adults: review of studies. Epilepsy Res Suppl 1: 23-47.
42. Specht U, Elsner H, May TW, Schimichowski B, Thorbecke R,. (2003) Postictal serum levels of antiepileptic drugs for detection of noncompliance. Epilepsy Behav 4: 487-495.
43. Speechley KN, Sang X, Levin S, Zou GY, Eliasziw M, Smith ML, Camfield C, Wiebe S,. (2008) Assessing severity of epilepsy in children: preliminary evidence of validity and reliability of a single-item scale. Epilepsy Behav 13: 337-342.
44. Suyagh M, Collier PS, Millership JS, Iheagwaram G, Millar M, Halliday HL, McElnay JC,. (2011) Metronidazole population pharmacokinetics in preterm neonates using dried blood-spot sampling. Pediatrics 127: e367-e734.
45. Takaki S, Kurokawa T, Aoyama T,. (1985) Monitoring drug noncompliance in epileptic patients: assessing phenobarbital plasma levels. Ther Drug Monit 7: 87-91.
46. Toublanc N, Sargentini-Maier ML, Lacroix B, Jacqmin P, Stockis A,. (2008) Retrospective population pharmacokinetic analysis of levetiracetam in children and adolescents with epilepsy: dosing recommendations. Clin Pharmacokinet 47: 333-341.
47. US Department of Health and Humans Services, Food and Drug Administration, FDA. (2001) Guidance for industry, bioanalytical method validation. Center for Drug Evaluation and Research (CDER), Rockville, MD.
48. Vovk T, Jakovljevic MB, Kos MK, Jankovic SM, Mrhar A, Grabnar I,. (2010) A nonlinear mixed effects modelling analysis of topiramate pharmacokinetics in patients with epilepsy. Biol Pharm Bull 33: 1176-1182.
49. World Health Organization. (2003) Adherence to long-term therapies: evidence for action. Available at: http://www.emro.who.int/ncd/Publications/ adherence-report.pdf (last accessed 1 September 2011).
50. Yukawa E, To H, Ohdo S, Higuchi S, Aoyama T,. (1997) Population-based investigation of valproic acid relative clearance using nonlinear mixed effects modeling: influence of drug-drug interaction and patient characteristics. J Clin Pharmacol 37: 1160-1167.
51. Zeber JE, Copeland LA, Pugh MJV,. (2010) Variation in antiepileptic drug adherence among older patients with new-onset epilepsy. Ann Pharmacother 44: 1896-1904.